Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - simvastatin - filmovertrukne tabletter - 80 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - hydrochlorthiazid, valsartan - filmovertrukne tabletter - 160+12,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - hydrochlorthiazid, valsartan - filmovertrukne tabletter - 80+12,5 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

actavis group ptc ehf - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminer til systemisk brug, - behandling af allergisk rhinitis og urticaria.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. virkning af imatinib om resultatet af bone marrow transplantation er ikke fastlagt. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. erfaringerne med imatinib i patienter med mds/mpd, der er forbundet med pdgfr gen re-arrangementer er meget begrænset. der er ingen kontrollerede undersøgelser, der påviser en klinisk fordel eller øget overlevelse for disse sygdomme.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - azathioprin - filmovertrukne tabletter - 50 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - bosentan, monohydrat - filmovertrukne tabletter - 125 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - buprenorphinhydrochlorid - resoribletter, sublinguale - 8 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - candesartancilexetil - tabletter - 16 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - candesartancilexetil - tabletter - 32 mg